Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 5/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22849934 | 0.90 | CETP (0.47) | CETPCHRM2CHRM1CHRM3TAAR1 | |
| SCHEMBL18896317 | 0.88 | CETP (0.48) | CETPCHRM2CHRM1CHRM3TAAR1 | |
| SCHEMBL13849933 | 0.84 | CETP (0.58) | CETPCHRM2CHRM1CHRM3GRM2 | |
| SCHEMBL22057166 | 0.84 | CETP (0.47) | CETPCHRM2CHRM1CHRM3CARM1 | |
| SCHEMBL14402392 | 0.84 | CETP (0.58) | CETPCHRM2CHRM1CHRM3GRM2 | |
| SCHEMBL13849901 | 0.84 | CETP (0.58) | CETPCHRM2CHRM1CHRM3GRM2 | |
| SCHEMBL2662597 | 0.83 | CETP (0.51) | CETPCHRM2CHRM1CHRM3TAAR1 | |
| SCHEMBL23095147 | 0.81 | ACACB (0.46) | — | |
| SCHEMBL14478257 | 0.81 | TAAR1 (0.65) | CETPCHRM2CHRM1CHRM3TAAR1 | |
| SCHEMBL18545945 | 0.81 | VNN1 (0.41) | CETPCHRM2CHRM1CHRM3TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10946000-B2 | Method for treating cancer with combination therapy | REDHILL BIOPHARMA LTD. (IL) | 2021-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10946000-B2 | Method for treating cancer with combination therapy | TPMT, KRAS, SDHA | CETP 3355/4885CHRM2 1446/4885CHRM1 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.